Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years
|Effective start/end date||4/1/16 → 3/31/20|
- Boehringer-Ingelheim Pharmaceuticals
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.